Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
Imagine the furore if a Conservative government announced a scheme to shrink hospital waiting lists using financial incentives. First, they’d pay cash-strapped hospitals unlimited bonuses to kick patients off the lists. Then, they’d offer GPs cash to stop referring patients…
NHS clinicians will be supported to use groundbreaking AI tools that bulldoze bureaucracy and take notes to free up staff time and deliver better care to patients thanks to guidance published today.
Read more here.
Attendees
Sponsors and Exhibitors
AI In Healthcare: A Virtual Course
Contact us